Sanofi’s Cablivi Receives EU Marketing Approval for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

 Sanofi’s Cablivi Receives EU Marketing Approval for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Sanofi’s Cablivi Receives EU Marketing Approval for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Shots:
  • The approval is based on P-II TITAN and P-III HERCULES studies enrolling 220 adults assessing Cablivi (caplacizumab) vs PBO, testing its safety and efficacy
  • P-III HERCULES results:  significantly shorter time to platelet count response, reduction in aTTP-related death, lower number of aTTPrecurrence, meaningful reduction in use of plasma exchange (PEX) compared to PBO
  • Cablivi was designated with Orphan Drug in EU and the US in 2009, in Switzerland and Japan in 2017 and 2018 respectively, additionally FDA has accepted priority review BLA with target action date 6 Feb, 2019

Click here to read full press release/ article | Ref: Sanofi | Image:  Sanofi

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post